Rebekka Niederer
Sankt Gallen, SG, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Journal: Med (New York, N.Y.)
Published: November 29, 2022
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Journal: Science immunology
Published: September 02, 2022
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Journal: Oncoimmunology
Published: December 03, 2021
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Journal: Journal of cancer research and clinical oncology
Published: July 26, 2021
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
Journal: JAMA oncology
Published: April 26, 2019
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: February 16, 2019
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.
Journal: Cancer management and research
Published: December 07, 2018
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Journal: Journal for immunotherapy of cancer
Published: September 10, 2018
Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy.
Journal: Science (New York, N.Y.)
Published: September 07, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026